MedPath

SciTech Development's ST-001 nanoFenretinide Advances to Phase 1b for T-Cell Lymphomas

• SciTech Development's ST-001 nanoFenretinide has progressed to the Phase 1b stage, focusing on clinical activity and response rates in T-cell lymphomas. • The Phase 1b trial is actively enrolling patients at nine medical centers across the United States, building on promising Phase 1a results. • A separate trial evaluating ST-001 in Small Cell Lung Cancer is scheduled to commence in the second quarter of 2025, expanding its potential application. • SciTech Development is dedicated to creating innovative and affordable cancer therapies to address unmet medical needs globally.

SciTech Development, Inc. has announced the advancement of its clinical trial for ST-001 nanoFenretinide to the Phase 1b stage. This phase will focus on a detailed evaluation of clinical activity and response rates in patients with T-cell lymphomas.
The Phase 1b trial is currently underway at nine medical centers throughout the United States. These centers are actively recruiting patients according to specific trial criteria. The advancement to this stage follows promising preliminary results from the accelerated Phase 1a trial.

Expansion to Small Cell Lung Cancer

In addition to the T-cell lymphoma trial, SciTech Development plans to initiate a separate trial in the second quarter of 2025 to investigate the efficacy of ST-001 nanoFenretinide in Small Cell Lung Cancer. This expansion indicates the company's commitment to exploring the therapeutic potential of ST-001 across various cancer types.

About ST-001 nanoFenretinide

ST-001 nanoFenretinide is an innovative cancer therapeutic developed by SciTech Development. The company aims to address unmet medical needs in oncology by creating effective and affordable treatments. SciTech Development is an oncology-focused pharmaceutical company committed to developing innovative cancer therapeutics.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Highlighted Clinical Trials

Related Topics

Denali and Takeda Open FTD-GRN Clinical Trial Site at UPenn

Denali Therapeutics and Takeda Pharmaceutical Company have initiated a phase 1/2 clinical trial for FTD caused by GRN mutations at the University of Pennsylvania, marking the first U.S.-based trial site. The study evaluates the safety and tolerability of DNL593, aiming to address progranulin deficits in FTD-GRN patients.

Instil Bio's Partner ImmuneOnco Doses First Patient in NSCLC Trial with IMM2510/SYN-2510

ImmuneOnco has dosed the first patient in a Phase 1b/2 trial of IMM2510/SYN-2510 with chemotherapy for advanced non-small cell lung cancer (NSCLC) in China.
Instil Bio anticipates initiating a U.S. clinical trial of SYN-2510/IMM2510 in first-line NSCLC patients in combination with chemotherapy in the second half of 2025.

Sensei Biotherapeutics Announces Key Milestones and Updates for Solnerstotug (SNS-101)

Sensei Biotherapeutics, Inc. has provided updates on its lead program, solnerstotug (SNS-101), highlighting key milestones including the anticipated full enrollment of the dose expansion arm by the end of Q1 2025 and a clinical data update expected in Q2 2025. The company is focused on advancing solnerstotug, a conditionally active antibody targeting the immune checkpoint VISTA, through its Phase 1/2 clinical trial for advanced solid tumors.

BioInvent's BI-1910 Shows Promise in Phase 1 Solid Tumor Trial

BioInvent's BI-1910 demonstrates stable disease in solid tumor patients as a single agent in Phase 1 dose escalation, with no notable adverse events.
The Phase 1 study of BI-1910 has expanded to Part B, evaluating its combination with Merck's anti-PD-1 therapy, Keytruda (pembrolizumab).

FDA Approves Phase 1/2 Clinical Trial for REC-4539 in Small Cell Lung Cancer

The FDA has cleared an investigational new drug application for REC-4539, a novel LSD1 inhibitor, marking the start of a phase 1/2 clinical trial targeting small cell lung cancer (SCLC) and other solid tumors. REC-4539 is distinguished by its CNS-penetrant and reversible properties, aiming to minimize platelet-related toxicities and improve safety profiles. The trial, named ENLYGHT, will explore REC-4539's efficacy both as a monotherapy and in combination with durvalumab, with patient dosing expected to begin in the first half of 2025.

Advancements in Tenosynovial Giant Cell Tumors Clinical Trials Highlighted for 2024

The Tenosynovial Giant Cell Tumors (TGCT) clinical trials landscape for 2024 showcases significant progress, with over 5 key companies developing more than 5 treatment therapies. Notable developments include the FDA's priority review for vimseltinib, a CSF1R inhibitor, and the EMA's acceptance of its Marketing Authorization Application, signaling a promising future for TGCT treatment.

Senhwa Biosciences Initiates Phase I/II Trial of Silmitasertib for Pediatric Solid Tumors

Senhwa Biosciences has dosed the first patient in a Phase I/II trial evaluating silmitasertib plus chemotherapy for relapsed or refractory solid tumors in children and young adults.
The study will determine the recommended dosage and assess the tolerability, safety, and efficacy of silmitasertib, particularly in neuroblastoma and sarcomas.

Panbela Therapeutics Initiates Phase I Trial of CPP-1X-S in STK11 Mutant NSCLC

Panbela Therapeutics has dosed the first patient in a Phase I trial evaluating CPP-1X-S (eflornithine sachets) in STK11 mutant non-small cell lung cancer (NSCLC).
The Phase I dose escalation study aims to determine the maximum tolerated dose of eflornithine in combination with Keytruda, an immune checkpoint inhibitor.

Stanford University Initiates Phase 1 Trial of B7-H3-Targeted CAR-T Therapy in Pediatric Solid Tumors

Stanford University has commenced a Phase 1 clinical trial to assess the safety and efficacy of CAR-T cell therapy targeting the B7-H3 antigen in pediatric patients with solid tumors.
The CAR-T cells are engineered from the patient's own T cells and enhanced with dasatinib to improve their ability to target and destroy cancer cells expressing B7-H3.

Traverse Biotech Receives NCI Grant to Develop Bispecific Antibody for Solid Tumors

Traverse Biotech has been awarded a Phase I SBIR grant from the NCI to advance its bispecific antibody for solid tumors, including non-small cell lung cancer.
The funding supports validation of Traverse Biotech's novel tumor antigen as a unique target for cancer immunotherapy.

Reference News

[1]
FDA Accepts IND Application for ST-001 in Relapsed/Refractory SCLC - Cancer Network
cancernetwork.com · Apr 9, 2025
[2]
SciTech Development Announces 2nd FDA Approval of a Phase 1 a/b IND For ST-001. New ...
biospace.com · Apr 8, 2025
[3]
SciTech Development Announces 2nd FDA Approval of a Phase 1 a/b IND For ST-001. New ...
prnewswire.com · Apr 8, 2025
[4]
FDA Clears IND Application for ST-001 in SCLC - Targeted Oncology
targetedonc.com · Apr 8, 2025
[5]
SciTech Development Advances to Next Stage of Clinical Trial for ST-001 nanoFenretinide
finance.yahoo.com · Jan 13, 2025

ST-001 nanoFenretinide advances to detailed clinical evaluation in T-cell lymphomas after successful Phase 1a, with tria...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy